Xuefeng Li

机构：Hubei University of Medicine, Jishou University, Hefei Institutes of Physical Science, Wenzhou Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Taihe Hospital, Yueyang Hospital, Cancer Hospital of Chinese Academy of Medical Sciences · ORCID：0000-0003-2033-7535

发表论文 86 篇 · 总被引 776 次 · h-index 13

代表论文

• Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial (2022 · Nature Medicine · 被引 95)
• Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial (2022 · Nature Medicine · 被引 76)
• Sodium–glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials (2021 · Acta Diabetologica · 被引 28)
• Incidence of Ischemia Reperfusion Injury Related Biliary Complications in Liver Transplantation: Effect of Different Types of Donors (2022 · Transplantation Proceedings · 被引 16)
• FUNDC1 modulates mitochondrial defects and pancreatic β-cell dysfunction under lipotoxicity (2023 · Biochemical and Biophysical Research Communications · 被引 14)
• Ten-day vonoprazan–amoxicillin dual therapy versus 14-day esomeprazole–amoxicillin dual therapy for first-line Helicobacter pylori eradication: a prospective multicenter randomized controlled trial (2024 · Therapeutic Advances in Gastroenterology · 被引 10)